Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1235865-75-4

Post Buying Request

1235865-75-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1235865-75-4 Usage

Uses

Methyl 4-Fluoro-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzoate is the intermediate for ABT 199 (A112430), which is a potent and selective BCL-2 inhibitor that achieves potent antitumor activity while sparing platelets. It’s practical application is to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer.

Check Digit Verification of cas no

The CAS Registry Mumber 1235865-75-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,5,8,6 and 5 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1235865-75:
(9*1)+(8*2)+(7*3)+(6*5)+(5*8)+(4*6)+(3*5)+(2*7)+(1*5)=174
174 % 10 = 4
So 1235865-75-4 is a valid CAS Registry Number.

1235865-75-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-fluorobenzoate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1235865-75-4 SDS

1235865-75-4Relevant articles and documents

Heterocyclic compounds as BCL-2 inhibitor

-

Paragraph 0093, (2021/04/17)

The present invention relates to a compound, a pharmaceutical composition containing the same, preparation method of the compound and thepharmaceutical composition, and uses ofthe compound and the pharmaceutical compositionas B-cell lymphoma-2 (BCL-2) inhibitors, wherein the compound is a compound shown as a formula I, or an isomer, a prodrug, a solvate, a stable isotope derivative or a pharmaceutically acceptable salt thereof. The invention also relates to the uses of the compound or the composition containing the same in treatment or prophylaxis of BCL2-mediated related diseases such as tumours.

Solid dispersions containing an apoptosis-inducing agent

-

, (2019/03/15)

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

PROCESS FOR THE PREPARATION OF VENETOCLAX

-

, (2018/03/06)

The present disclosure provides novel synthetic process for the preparation of venetoclax. The disclosed processes involve the use of novel intermediates. Processes for the preparation of these intermediates are also disclosed as well as methods for the preparation of particularly useful salts thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1235865-75-4